Elsevier

Seminars in Immunology

Volume 26, Issue 1, February 2014, Pages 13-19
Seminars in Immunology

Review
Inhibition of IL-6 family cytokines by SOCS3

https://doi.org/10.1016/j.smim.2013.12.004Get rights and content

Highlights

  • SOCS3 is the primary feedback inhibitor of IL-6 family signalling.

  • SOCS3 controls the duration of IL-6 signalling and shapes the cells response to it.

  • SOCS3 binds to gp130, the shared IL-6 family co-receptor.

  • SOCS3 directly inhibits JAK1, JAK2 and TYK2 but not JAK3.

  • SOCS3 targets gp130/JAK complexes.

Abstract

IL-6 a multi-functional cytokine with important effects in both inflammation and haematopoiesis. SOCS3 is the primary inhibitor of IL-6 signalling, interacting with gp130, the common shared chain of the IL-6 family of cytokines, and JAK1, JAK2 and TYK2 to control both the duration of signalling and the biological response. Recent biochemical and structural studies have shown SOCS3 binds to only these three JAKs, all of which are associated with IL-6 signalling, and not JAK3. This specificity is determined by a three residue “GQM” motif in the kinase domain of JAK1, JAK2 and TYK2. SOCS3 binds to JAK and gp130 simultaneously, and inhibits JAK activity in an ATP-independent manner by partially occluding the kinase's substrate binding groove with its kinase inhibitory region. We therefore propose a model in which each of gp130, JAK and SOCS3 are directly bound to the other two, allowing SOCS3 to inhibit IL6 signalling with high potency and specificity.

Section snippets

Introduction: IL-6 signalling

IL-6 is a pleiotropic cytokine that exerts both inflammatory and anti-inflammatory effects depending upon its cellular context and is an important differentiation factor during haematopoiesis (reviewed in [1]). IL-6 belongs to a family of cytokines that also include IL-11, IL-27, LIF, OSM, CT-1 and CNTF. These cytokines are structurally similar [2] and signal via association with cell-surface trans-membrane receptors that each consist of a dimer (or higher-order oligomer) of the common shared

Discovery of the SOCS proteins

In 1997 the SOCS family of proteins were discovered concurrently by the groups of Hilton (Walter and Eliza Hall Institute, Australia), Yoshimura (Kurume University, Japan) and Kishimoto (Osaka University, Japan) [16], [17], [18]. Each group used a different approach. Hilton et al., used an expression cloning methodology to identify proteins capable of inhibiting the IL-6-induced differentiation of the mouse M1 myelomonocytic cell-line and discovered, and named, SOCS1 (Suppressor of Cytokine

The SOCS family

Evolutionarily, SOCS proteins are first seen in animals having bilateral symmetry [23]. Recent analyses suggest the existence of three SOCS proteins in these organisms: orthologues of CIS/SOCS1/SOCS2/SOCS3 as well as SOCS4/5 and SOCS6/7 [23], [24]. Whilst certain species, most notably the fruit fly Drosophila melanogaster have lost one or more of these three subgroups, they are all represented in vertebrates where they have expanded to form the eight family members seen in mammals. Of these

SOCS3 is the primary regulator of IL-6 signalling

Despite SOCS1 being discovered on the basis of its ability to inhibit IL-6 action when overexpressed [17], [18], genetic deletion studies have surprisingly shown that SOCS1 plays little, if any, role in inhibiting IL-6 in vivo [43]. Rather it is SOCS3 that is the family member responsible for inhibiting IL-6 under physiological conditions [44], [45], [46]. This is a cautionary tale regarding the interpretation of the effects of individual SOCS proteins on various cytokines; whilst many SOCS

SOCS3 controls the duration of IL-6 signalling

Genetic deletion of SOCS3 in mice is lethal due to placental insufficiency as a result of dysregulated signalling by LIF [48]. Therefore, confirmation of the important role that SOCS3 plays in regulating signalling by other IL-6 family members, including IL-6 itself, has been via conditional knockout of the Socs3 gene. The first such studies were knockouts of SOCS3 in hepatocytes [46] and macrophages [44] (using cre recombinase under control of the Albumin or LysM promoters respectively) and

SOCS3 shapes the cell's response to IL-6

As well as controlling the duration of IL-6 signalling, SOCS3 also helps shape the cell's response to IL-6. For example, the transcriptional output of Socs3−/− macrophages stimulated with IL-6 differs not just quantitatively but also qualitatively from that of wild-type cells. In particular, loss of SOCS3 leads to an IL-6-induced transcriptional response that in part resembles that for interferon-γ with a number of interferon-inducible genes being switched on by IL-6 in these cells [51].

SOCS3 interacts with gp130, the shared receptor for IL-6 family cytokines

STAT3 is activated by a number of different cytokines and is a powerful inducer of SOCS3 expression [54]. However, SOCS3 only feeds back to inhibit STAT3 that is activated in response to particular cytokines (for example IL-6) and not others (for example IL-10 or interferon-γ) [44], [51], [55]. The key to this specificity is that SOCS3 directly interacts with gp130, the co-receptor for IL-6 family cytokines [56], [57], [58]. This allows SOCS3 to specifically target the IL-6 signalling cascade

The kinase inhibitory region (KIR) of SOCS3 allows it to directly inhibit JAK's catalytic activity

SOCS3 in mice and humans is a 225 amino acid protein that, like all SOCS proteins, contains an SH2 domain (residues 45–185) and a SOCS box domain (residues 186–225) [18], [22]. SOCS3 also contains a short N-terminal segment (residues 1–44), the most notable feature of which is the so-called Kinase Inhibitory Region (KIR) [77], [78], [79], [80], an 8–12 amino acid sequence that allows it to directly inhibit JAK's catalytic domain and is absolutely required for function (Fig. 2b).

The existence of

SOCS3 inhibits JAK1, JAK2 and TYK2 but not JAK3

Whilst the KIR is required to inhibit JAK, it is not sufficient. There is no detectable inhibition of JAK using a SOCS3 KIR peptide [82]. The structure of SOCS3 bound to JAK2 shows that only approximately 20% of the buried surface area within the complex involves the KIR. The majority of the SOCS3:JAK affinity is derived from an interaction between the SH2 domain of SOCS3 and JAK. It is important to note that this does not involve the classical phosphotyrosine binding groove on the SH2 domain,

A model of SOCS3 inhibition of IL-6 signalling

Knockout studies have shown that SOCS3 is a highly potent and specific inhibitor of IL-6 family cytokines, G-CSF and leptin, despite the fact that its expression is induced by a much larger number of cytokines. Any model of SOCS3 action must explain this specificity. Our model is centred upon the fact that SOCS3 binds JAK and the IL-6 receptor simultaneously via two opposing surfaces. Thus it is a particular JAK/receptor complex that is the true target of SOCS3, rather than an individual JAK or

Acknowledgments

The original research described in this review was supported by the National Health and Medical Research Council of Australia (programme grant nos. 461219 and 487922, 1011804), the U.S. National Institutes of Health (grant no. CA22556), the Victorian State Government Operational Infrastructure Support Grant, and the NHMRC Independent Research Institutes Infrastructure Support Scheme (361646). N.A.N. acknowledges fellowship support from the National Health and Medical Research Council, L.N.V.

References (86)

  • J.R. Muniz et al.

    Molecular architecture of the ankyrin SOCS box family of Cul5-dependent E3 ubiquitin ligases

    J Mol Biol

    (2013)
  • A.N. Bullock et al.

    Structure of the SOCS4–ElonginB/C complex reveals a distinct SOCS box interface and the molecular basis for SOCS-dependent EGFR degradation

    Structure

    (2007)
  • J.J. Babon et al.

    The SOCS box domain of SOCS3: structure and interaction with the elonginBC-cullin5 ubiquitin ligase

    J Mol Biol

    (2008)
  • K. Boyle et al.

    The SOCS box of suppressor of cytokine signaling-3 contributes to the control of G-CSF responsiveness in vivo

    Blood

    (2007)
  • K. Boyle et al.

    Deletion of the SOCS box of suppressor of cytokine signaling 3 (SOCS3) in embryonic stem cells reveals SOCS box-dependent regulation of JAK but not STAT phosphorylation

    Cell Signal

    (2009)
  • C.J. Greenhalgh et al.

    Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling

    J Biol Chem

    (2002)
  • E. Kario et al.

    Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling

    J Biol Chem

    (2005)
  • F. Verdier et al.

    Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation. Possible involvement of the ubiquitinated Cis protein

    J Biol Chem

    (1998)
  • P.A. Ram et al.

    Role of the cytokine-inducible SH2 protein CIS in desensitization of STAT5b signaling by continuous growth hormone

    J Biol Chem

    (2000)
  • W.S. Alexander et al.

    SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine

    Cell

    (1999)
  • B.A. Croker et al.

    SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis

    Immunity

    (2004)
  • P. Kievit et al.

    Enhanced leptin sensitivity and improved glucose homeostasis in mice lacking suppressor of cytokine signaling-3 in POMC-expressing cells

    Cell Metab

    (2006)
  • B.A. Croker et al.

    Socs3 maintains the specificity of biological responses to cytokine signals during granulocyte and macrophage differentiation

    Exp Hematol

    (2008)
  • S. Wormald et al.

    The comparative roles of suppressor of cytokine signaling-1 and -3 in the inhibition and desensitization of cytokine signaling

    J Biol Chem

    (2006)
  • J. Schmitz et al.

    SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130

    J Biol Chem

    (2000)
  • U. Lehmann et al.

    SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130

    J Biol Chem

    (2003)
  • E. Bergamin et al.

    Structural basis for phosphotyrosine recognition by suppressor of cytokine signaling-3

    Structure

    (2006)
  • T. Pawson et al.

    SH2 and SH3 domains: from structure to function

    Cell

    (1992)
  • J.J. Babon et al.

    The structure of SOCS3 reveals the basis of the extended SH2 domain function and identifies an unstructured insertion that regulates stability

    Mol Cell

    (2006)
  • A. Sasaki et al.

    The N-terminal truncated isoform of SOCS3 translated from an alternative initiation AUG codon under stress conditions is stable due to the lack of a major ubiquitination site, Lys-6

    J Biol Chem

    (2003)
  • S. Haan et al.

    Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation

    J Biol Chem

    (2003)
  • T. Fukada et al.

    Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis

    Immunity

    (1996)
  • A. Sasaki et al.

    CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2

    J Biol Chem

    (2000)
  • J.J. Babon et al.

    Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity

    Immunity

    (2012)
  • M.M. Song et al.

    The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities

    J Biol Chem

    (1998)
  • P.A. Ram et al.

    SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms

    J Biol Chem

    (1999)
  • R.S. Depetris et al.

    Structural basis for inhibition of the insulin receptor by the adaptor protein Grb14

    Mol Cell

    (2005)
  • X. Wang et al.

    Structural biology of shared cytokine receptors

    Annu Rev Immunol

    (2009)
  • T. Taga et al.

    Gp130 and the interleukin-6 family of cytokines

    Annu Rev Immunol

    (1997)
  • M.J. Boulanger et al.

    Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex

    Science

    (2003)
  • S. Rose-John et al.

    Soluble receptors for cytokines and growth factors: generation and biological function

    Biochem J

    (1994)
  • J. Feng et al.

    Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop

    Mol Cell Biol

    (1997)
  • Cited by (0)

    View full text